ID

19043

Description

Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00582556

Lien

https://clinicaltrials.gov/show/NCT00582556

Mots-clés

Versions (1)
  1. 01/12/2016 01/12/2016 -
Téléchargé le

1 décembre 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Prostate Cancer NCT00582556

Anglais

Eligibility Prostate Cancer NCT00582556

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
must have a histologic diagnosis of adenocarcinoma of the prostate.
Description

Adenocarcinoma of prostate

Type de données

boolean

Alias
UMLS CUI [1]
C0007112
for patients without clinical metastasis treated by surgery, serum psa values must be > 0.2 ng/ml by two measurements at least two weeks apart. in patients treated with ablative radiation therapy without clinical metastasis, three consecutive increases in serum psa must be documented, with at least a one-month interval between values with the final psa > 2ng/m as evidence of biochemical psa failure. p
Description

Neoplasm Metastasis | Operative Surgical Procedures | Prostate specific antigen measurement Quantity | Therapeutic radiology procedure Ablation | Serum Prostate Specific Antigen Increased Quantity | PSA Failure Evidence of

Type de données

boolean

Alias
UMLS CUI [1]
C0027627
UMLS CUI [2]
C0543467
UMLS CUI [3,1]
C0201544
UMLS CUI [3,2]
C1265611
UMLS CUI [4,1]
C1522449
UMLS CUI [4,2]
C0547070
UMLS CUI [5,1]
C1883014
UMLS CUI [5,2]
C1265611
UMLS CUI [6,1]
C2985506
UMLS CUI [6,2]
C0332120
patients who have not had prior primary therapy such as radiation or surgery, are required to have a detectable psa of at least 0.2 ng/ml.
Description

First line treatment | Therapeutic radiology procedure | Operative Surgical Procedures | Prostate specific antigen measurement | Prostate-Specific Antigen Detectable

Type de données

boolean

Alias
UMLS CUI [1]
C1708063
UMLS CUI [2]
C1522449
UMLS CUI [3]
C0543467
UMLS CUI [4]
C0201544
UMLS CUI [5,1]
C0138741
UMLS CUI [5,2]
C3830527
patients with evidence of metastatic disease are eligible irrespective of serum psa level.
Description

Neoplasm Metastasis Evidence of | Prostate specific antigen measurement

Type de données

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C0332120
UMLS CUI [2]
C0201544
prior history of a second malignancy is allowed if treated with curative intent and patient has been free of disease greater than five years
Description

Malignant Neoplasm second Curative treatment | Disease Free of

Type de données

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0205436
UMLS CUI [1,3]
C1273390
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C0332296
ecog performance status of < 2.
Description

ECOG performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior treatment with a gnrh analogue or anti-androgen.
Description

GnRH analog | Androgen Antagonists

Type de données

boolean

Alias
UMLS CUI [1]
C1518041
UMLS CUI [2]
C0002842
evidence of immunosuppression or have been treated with immunosuppressive therapy, such as chemotherapy, chronic treatment dose corticosteroids, or radiation therapy to bones, within 6 months of study enrollment
Description

Immunosuppression Evidence of | Therapeutic immunosuppression | Chemotherapy | Adrenal Cortex Hormones Dose chronic | Therapeutic radiology procedure Bone

Type de données

boolean

Alias
UMLS CUI [1,1]
C4048329
UMLS CUI [1,2]
C0332120
UMLS CUI [2]
C0021079
UMLS CUI [3]
C0392920
UMLS CUI [4,1]
C0001617
UMLS CUI [4,2]
C0178602
UMLS CUI [4,3]
C0205191
UMLS CUI [5,1]
C1522449
UMLS CUI [5,2]
C0262950
current or treatment within 4 weeks with estrogen or estrogenic agents (including herbal compound pc-spes)
Description

Estrogens | herbal preparation PC-SPES

Type de données

boolean

Alias
UMLS CUI [1]
C0014939
UMLS CUI [2]
C0756934
current or treatment within 4 weeks with herbal compounds for prostate cancer such as pc-spes or saw palmetto
Description

Plant Preparations Prostate carcinoma | PC-SPES | Saw palmetto extract

Type de données

boolean

Alias
UMLS CUI [1,1]
C0949854
UMLS CUI [1,2]
C0600139
UMLS CUI [2]
C0756934
UMLS CUI [3]
C0771607
current or treatment within 4 weeks with megestrol
Description

Megestrol

Type de données

boolean

Alias
UMLS CUI [1]
C0025175
current or prior treatment with a bisphosphonate, calcitonin, or other bone resorptive/anabolic agents
Description

Diphosphonates | Calcitonin | Pharmaceutical Preparations Bone Resorption | Anabolic Agents

Type de données

boolean

Alias
UMLS CUI [1]
C0012544
UMLS CUI [2]
C0006668
UMLS CUI [3,1]
C0013227
UMLS CUI [3,2]
C0005974
UMLS CUI [4]
C1258800
current use of oral corticosteroids or any such use within the past 6 months
Description

Adrenal Cortex Hormones Oral

Type de données

boolean

Alias
UMLS CUI [1,1]
C0001617
UMLS CUI [1,2]
C1527415
current use of potentially bone-toxic anticonvulsants (phenytoin, or carbamazepine)
Description

Anticonvulsants Toxic effect Bone | Phenytoin | Carbamazepine

Type de données

boolean

Alias
UMLS CUI [1,1]
C0003286
UMLS CUI [1,2]
C0600688
UMLS CUI [1,3]
C0262950
UMLS CUI [2]
C0031507
UMLS CUI [3]
C0006949
history of orchiectomy
Description

Orchiectomy

Type de données

boolean

Alias
UMLS CUI [1]
C0029189
hypocalcemia
Description

Hypocalcemia

Type de données

boolean

Alias
UMLS CUI [1]
C0020598
Retour au début de la page

Similar models

Eligibility Prostate Cancer NCT00582556

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Adenocarcinoma of prostate
Item
must have a histologic diagnosis of adenocarcinoma of the prostate.
boolean
C0007112 (UMLS CUI [1])
Neoplasm Metastasis | Operative Surgical Procedures | Prostate specific antigen measurement Quantity | Therapeutic radiology procedure Ablation | Serum Prostate Specific Antigen Increased Quantity | PSA Failure Evidence of
Item
for patients without clinical metastasis treated by surgery, serum psa values must be > 0.2 ng/ml by two measurements at least two weeks apart. in patients treated with ablative radiation therapy without clinical metastasis, three consecutive increases in serum psa must be documented, with at least a one-month interval between values with the final psa > 2ng/m as evidence of biochemical psa failure. p
boolean
C0027627 (UMLS CUI [1])
C0543467 (UMLS CUI [2])
C0201544 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C1522449 (UMLS CUI [4,1])
C0547070 (UMLS CUI [4,2])
C1883014 (UMLS CUI [5,1])
C1265611 (UMLS CUI [5,2])
C2985506 (UMLS CUI [6,1])
C0332120 (UMLS CUI [6,2])
First line treatment | Therapeutic radiology procedure | Operative Surgical Procedures | Prostate specific antigen measurement | Prostate-Specific Antigen Detectable
Item
patients who have not had prior primary therapy such as radiation or surgery, are required to have a detectable psa of at least 0.2 ng/ml.
boolean
C1708063 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C0543467 (UMLS CUI [3])
C0201544 (UMLS CUI [4])
C0138741 (UMLS CUI [5,1])
C3830527 (UMLS CUI [5,2])
Neoplasm Metastasis Evidence of | Prostate specific antigen measurement
Item
patients with evidence of metastatic disease are eligible irrespective of serum psa level.
boolean
C0027627 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
C0201544 (UMLS CUI [2])
Malignant Neoplasm second Curative treatment | Disease Free of
Item
prior history of a second malignancy is allowed if treated with curative intent and patient has been free of disease greater than five years
boolean
C0006826 (UMLS CUI [1,1])
C0205436 (UMLS CUI [1,2])
C1273390 (UMLS CUI [1,3])
C0012634 (UMLS CUI [2,1])
C0332296 (UMLS CUI [2,2])
ECOG performance status
Item
ecog performance status of < 2.
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
GnRH analog | Androgen Antagonists
Item
prior treatment with a gnrh analogue or anti-androgen.
boolean
C1518041 (UMLS CUI [1])
C0002842 (UMLS CUI [2])
Immunosuppression Evidence of | Therapeutic immunosuppression | Chemotherapy | Adrenal Cortex Hormones Dose chronic | Therapeutic radiology procedure Bone
Item
evidence of immunosuppression or have been treated with immunosuppressive therapy, such as chemotherapy, chronic treatment dose corticosteroids, or radiation therapy to bones, within 6 months of study enrollment
boolean
C4048329 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
C0021079 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C0001617 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0205191 (UMLS CUI [4,3])
C1522449 (UMLS CUI [5,1])
C0262950 (UMLS CUI [5,2])
Estrogens | herbal preparation PC-SPES
Item
current or treatment within 4 weeks with estrogen or estrogenic agents (including herbal compound pc-spes)
boolean
C0014939 (UMLS CUI [1])
C0756934 (UMLS CUI [2])
Plant Preparations Prostate carcinoma | PC-SPES | Saw palmetto extract
Item
current or treatment within 4 weeks with herbal compounds for prostate cancer such as pc-spes or saw palmetto
boolean
C0949854 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C0756934 (UMLS CUI [2])
C0771607 (UMLS CUI [3])
Megestrol
Item
current or treatment within 4 weeks with megestrol
boolean
C0025175 (UMLS CUI [1])
Diphosphonates | Calcitonin | Pharmaceutical Preparations Bone Resorption | Anabolic Agents
Item
current or prior treatment with a bisphosphonate, calcitonin, or other bone resorptive/anabolic agents
boolean
C0012544 (UMLS CUI [1])
C0006668 (UMLS CUI [2])
C0013227 (UMLS CUI [3,1])
C0005974 (UMLS CUI [3,2])
C1258800 (UMLS CUI [4])
Adrenal Cortex Hormones Oral
Item
current use of oral corticosteroids or any such use within the past 6 months
boolean
C0001617 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
Anticonvulsants Toxic effect Bone | Phenytoin | Carbamazepine
Item
current use of potentially bone-toxic anticonvulsants (phenytoin, or carbamazepine)
boolean
C0003286 (UMLS CUI [1,1])
C0600688 (UMLS CUI [1,2])
C0262950 (UMLS CUI [1,3])
C0031507 (UMLS CUI [2])
C0006949 (UMLS CUI [3])
Orchiectomy
Item
history of orchiectomy
boolean
C0029189 (UMLS CUI [1])
Hypocalcemia
Item
hypocalcemia
boolean
C0020598 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial